MedTrace Logo

Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN

NCT07592663 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 708

Last updated 2026-05-18

No results posted yet for this study

Summary

Solid pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant tumor primarily treated with surgical resection. However, the oncologic safety of parenchyma-sparing resection (PSR) and the necessity of lymphadenectomy remain debated. This prospective cohort study evaluates these aspects based on long-term outcomes.

Conditions

  • Pancreatic Tumor, Benign
  • Solid Pseudopapillary Tumor of the Pancreas

Interventions

PROCEDURE

Parenchyma-sparing resection

PSR included enucleation (EN), duodenum-preserving pancreatic head resection (DPPHR), central pancreatectomy (CP), and spleen-preserving distal pancreatectomy (SPDP). OR included pancreatoduodenectomy (PD), distal pancreatectomy with splenectomy (DPS), and total pancreatectomy (TP).

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xianjun Yu, MD, PhD · Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China

  • Xiaowu Xu, MD, PhD · Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China

  • Zheng Li, MD · Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center Shanghai, Shanghai, China

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-01
Primary Completion
2026-03-01
Completion
2026-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07592663 on ClinicalTrials.gov